Your browser is no longer supported. Please, upgrade your browser.
Settings
SRPT Sarepta Therapeutics, Inc. daily Stock Chart
SRPT [NASD]
Sarepta Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.44 Insider Own0.90% Shs Outstand63.89M Perf Week5.05%
Market Cap2.99B Forward P/E- EPS next Y-1.76 Insider Trans-8.66% Shs Float60.37M Perf Month27.01%
Income-124.20M PEG- EPS next Q-0.91 Inst Own68.30% Short Float20.66% Perf Quarter40.59%
Sales56.80M P/S52.68 EPS this Y-5.50% Inst Trans4.71% Short Ratio4.77 Perf Half Y53.79%
Book/sh6.87 P/B6.82 EPS next Y-43.10% ROA-26.50% Target Price67.94 Perf Year66.36%
Cash/sh4.71 P/C9.94 EPS next 5Y-0.20% ROE-32.00% 52W Range26.26 - 63.73 Perf YTD70.73%
Dividend- P/FCF- EPS past 5Y- ROI-75.60% 52W High-26.52% Beta1.03
Dividend %- Quick Ratio5.30 Sales past 5Y-35.10% Gross Margin98.40% 52W Low78.33% ATR1.92
Employees197 Current Ratio5.90 Sales Q/Q- Oper. Margin- RSI (14)67.23 Volatility3.58% 4.48%
OptionableYes Debt/Eq0.03 EPS Q/Q15.00% Profit Margin- Rel Volume0.69 Prev Close46.83
ShortableYes LT Debt/Eq0.00 EarningsOct 18 AMC Payout- Avg Volume2.62M Price46.83
Recom1.80 SMA2013.14% SMA5019.02% SMA20039.26% Volume0 Change0.00%
Jul-20-17Reiterated RBC Capital Mkts Outperform $60 → $64
Apr-28-17Reiterated RBC Capital Mkts Outperform $91 → $60
Apr-05-17Upgrade SunTrust Hold → Buy
Mar-02-17Upgrade Leerink Partners Mkt Perform → Outperform
Mar-02-17Initiated Instinet Buy $84
Mar-01-17Reiterated RBC Capital Mkts Outperform $98 → $91
Feb-22-17Reiterated Needham Buy $81 → $78
Jan-04-17Reiterated Morgan Stanley Equal-Weight $53 → $33
Dec-22-16Initiated JP Morgan Overweight $40
Dec-20-16Initiated Goldman Neutral
Dec-16-16Reiterated RBC Capital Mkts Outperform $106 → $98
Dec-14-16Reiterated Jefferies Hold $46 → $32
Oct-28-16Reiterated RBC Capital Mkts Outperform $108 → $106
Oct-27-16Initiated Morgan Stanley Equal-Weight $53
Oct-18-16Initiated Credit Suisse Outperform $68
Oct-10-16Reiterated Wedbush Outperform $66 → $72
Sep-28-16Reiterated RBC Capital Mkts Outperform $83 → $108
Sep-20-16Reiterated Needham Buy $47 → $81
Sep-19-16Upgrade RBC Capital Mkts Sector Perform → Outperform $5 → $83
Sep-19-16Upgrade Jefferies Underperform → Hold
Sep-12-17 08:05AM  See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc. Markit
Sep-11-17 07:38AM  What Analysts Recommend for BioMarin Pharmaceuticals in September Market Realist
Sep-07-17 02:11PM  Sarepta Therapeutics Chart Patterns Look Good TheStreet.com
01:23PM  Sarepta's Golodirsen Positive in DMD Study, Shares Soar Zacks
12:52PM  [$$] Sarepta: Turbocharge Returns With Options Barrons.com
09:15AM  One Worry Off the Table (Until December) Zacks
08:10AM  Today's Research Reports on Stocks to Watch: Sarepta Therapeutics and Myriad Genetics ACCESSWIRE
06:54AM  Sareptas positive trial results for new DMD treatment could reopen rare disease drug controversy MarketWatch
Sep-06-17 04:57PM  What Happened in the Stock Market Today Motley Fool +13.75%
02:02PM  This Controversial Biotech May Yet Defy Its Skeptics Fortune
01:59PM  Can you trust Facebook? It's in the Blitz CNBC Videos
01:29PM  We May Soon Learn Just How Flexible Scott Gottlieb's FDA Is Bloomberg
01:20PM  Is There Now An Opportunity In Sarepta Therapeutics Inc (SRPT)? Simply Wall St.
12:30PM  Why Sareptas latest trial data may presage another FDA controversy American City Business Journals
12:09PM  Why Sarepta Therapeutics Stock Is Rising Today Motley Fool
11:39AM  [$$] Soaring Sarepta Can Continue to Stay Hot Barrons.com
10:30AM  CEO defends $300,000-per-year cost for a drug for a rare form of muscular dystrophy CNBC
09:21AM  Stocks to Watch: Hewlett Packard Enterprise, Fiat Chrysler, Exxon Mobil, Sarepta Therapeutics, G-III Apparel Group The Wall Street Journal
08:41AM  Shares of drugmaker that targets gene mutations soar after positive study results CNBC
08:30AM  Sarepta Therapeutics to Ring Nasdaq Stock Market Closing Bell in Recognition of World Duchenne Awareness Day GlobeNewswire
08:14AM  Sarepta stock jumps on muscular dystrophy drug trial resu... CNBC Videos
08:02AM  See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc. Markit
07:32AM  Sarepta shares surge 14% on positive early/mid-stage clinical trial results in DMD MarketWatch
07:00AM  Sarepta Therapeutics Announces Positive Results in Its Study Evaluating Gene Expression, Dystrophin Production, and Dystrophin Localization in Patients with Duchenne Muscular Dystrophy (DMD) Amenable to Skipping Exon 53 Treated with Golodirsen (SRP-4053) GlobeNewswire
Sep-05-17 12:31PM  Sarepta: Time to Buy? Barrons.com
10:00AM  Sarepta Therapeutics, Inc. (Nasdaq: SRPT) to Ring The Nasdaq Stock Market Closing Bell GlobeNewswire
Sep-04-17 08:04AM  See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc. Markit
Aug-31-17 06:30PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Aug-30-17 04:11PM  Edited Transcript of SRPT earnings conference call or presentation 19-Jul-17 8:30pm GMT Thomson Reuters StreetEvents
Aug-29-17 10:40PM  Sarepta Therapeutics, Inc. Value Analysis (NASDAQ:SRPT) : August 30, 2017 Capital Cube
Aug-27-17 07:27AM  3 Biotech Stocks That Could Soar in September Motley Fool
Aug-24-17 08:30AM  Sarepta Therapeutics to Present at Three Upcoming Investor Conferences GlobeNewswire
Aug-23-17 08:01AM  See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc. Markit
Aug-22-17 09:04AM  Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : SRPT-US : August 22, 2017 Capital Cube
08:43AM  Why Is Sarepta (SRPT) Down 9.9% Since the Last Earnings Report? Zacks
Aug-16-17 08:01AM  See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc. Markit
08:00AM  Today's Research Reports on Trending Tickers: Exelixis Inc. and Sarepta Therapeutics Inc. ACCESSWIRE
Aug-12-17 08:03AM  See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc. Markit
Aug-11-17 08:03AM  See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc. Markit
Aug-10-17 08:03AM  IHS Markit Score Update: Drop in demand for ETFs holding Sarepta Therapeutics Inc is a negative sign for its shares Markit
Aug-09-17 08:04AM  See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc. Markit
Aug-07-17 09:31AM  These 3 Biotechs Just Crushed Analyst Expectations Motley Fool
Aug-04-17 07:40AM  Why Sarepta Therapeutics Stock Gained 10.7% in July Motley Fool
Aug-03-17 06:51PM  [$$] FDA Emails Offer Rare Look Into Internal Battle Over a Drug's Approval The Wall Street Journal
09:38AM  BioMarin (BMRN) Q2 Loss Narrows, Sales Surpass Estimates Zacks
Aug-01-17 08:00AM  Today's Research Reports on Trending Tickers: Sarepta Therapeutics Inc. and GW Pharmaceuticals Plc ACCESSWIRE
Jul-31-17 06:30PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire -5.46%
Jul-27-17 08:30AM  Sarepta Therapeutics Announces its Partner, Genethon, Published New Micro-Dystrophin Gene Therapy Data in Nature Communications GlobeNewswire
Jul-24-17 09:43PM  3 Stocks With MercadoLibre-Like Return Potential Motley Fool
08:00PM  Sarepta Therapeutics Announces Pricing of $325 Million Public Offering of Common Stock GlobeNewswire
04:55PM  This Biotech Got A Price Hike, But Seesawed After A Three-Day Run Investor's Business Daily
12:15PM  Sarepta may look to bolster pipeline after $250M offering American City Business Journals
07:00AM  Sarepta Therapeutics Announces Proposed $250 Million Public Offering of Common Stock GlobeNewswire
Jul-22-17 12:46AM  [$$] Sarepta's Sales Ramp Up Barrons.com
Jul-21-17 12:57PM  William Blair Bullish on Biotech: Sarepta Therapeutics Inc (SRPT), Dynavax Technologies Corporation (DVAX), and Exelixis, Inc. (EXEL) SmarterAnalyst +6.06%
08:00AM  Today's Research Reports on Stocks to Watch: Sarepta Therapeutics and Kite Pharma Accesswire
Jul-20-17 05:52PM  [$$] Sarepta Can Rally Further As Key Drug Gains Sales Barrons.com +20.10%
04:24PM  Why Kinder Morgan, Ambac Financial, and Sarepta Therapeutics Jumped Today Motley Fool
04:14PM  This Biotech Just Blew Past Its Buy Point On A $13 Million Sales Beat Investor's Business Daily
01:09PM  Sarepta Therapeutics (SRPT) Stock Surged 24% Today: Here's Why Zacks
11:36AM  Sarepta Therapeutics Inc (SRPT) Soars on Q2 Revenue, Forecast InvestorPlace
11:29AM  Story Stocks from Briefing.com Briefing.com
10:43AM  Sarepta (SRPT) Q2 Loss Narrows, Ups Exondys 51 Sales View Zacks
09:38AM  Biotech Movers: Sarepta, Inovio, Mylan TheStreet.com
09:30AM  Sarepta rockets 20% higher after 'powerhouse' biotech tops revenue expectations CNBC
08:18AM  Sarepta Therapeutics Incs (SRPT) Earnings Trigger Price Target Boost; Shares Soar 18% SmarterAnalyst
07:30AM  Why Sarepta Therapeutics Stock Rose After-Hours Wednesday Motley Fool
07:30AM  Why Sarepta Therapeutics Stock Is Rising Today Motley Fool
Jul-19-17 09:16PM  Sarepta Therapeutics reports 2Q loss Associated Press
05:37PM  Sarepta shoots higher as sales of $300,000-a-year drug exceed expectations MarketWatch
04:56PM  Sarepta & BioMarin Settle Patent Litigation on Exon Skipping Zacks
04:31PM  Sarepta hikes full-year sales estimate for Duchenne drug American City Business Journals
04:22PM  Sarepta Rockets On Consensus-Crushing Sales, Narrowing Losses Investor's Business Daily
04:01PM  Sarepta Therapeutics Announces Second Quarter 2017 Financial Results and Recent Corporate Developments GlobeNewswire
01:45PM  Sarepta skips over a Duchenne patent battle with $35M settlement American City Business Journals
11:00AM  Investor Network: Sarepta Therapeutics, Inc. to Host Earnings Call Accesswire
08:30AM  Sarepta Therapeutics and Clinigen Launch a Managed Access Program to Treat Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping GlobeNewswire
Jul-18-17 04:30PM  Sarepta Therapeutics Secures $100 Million in Debt Financing GlobeNewswire
01:45PM  BioMarin snags cash as Sarepta skips Duchenne patent battle American City Business Journals
01:32PM  Sarepta, BioMarin Fall After Settling Patent Fight Barrons.com
08:30AM  Sarepta Therapeutics and BioMarin Pharmaceutical Inc. Announce Execution of a Global Settlement and a License Agreement Resolving Exon Skipping Patent Litigation GlobeNewswire
Jul-17-17 04:33PM  How These Biotechs Are Dodging Payor Pushback In Muscular Dystrophy Investor's Business Daily
10:55AM  Sarepta Therapeutics: Say Hello To The New CEO Barrons.com
Jul-12-17 09:30AM  The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Alimera Sciences, Enzo Biochem, Sarepta Therapeutics and EXACT Sciences Zacks
07:01AM  Why Sarepta Therapeutics Stock Picked Up Steam in June Motley Fool
Jul-11-17 09:26AM  5 Top Multibagger Biotech Stocks to Buy in the 2nd Half Zacks
Jun-30-17 06:00PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
10:47AM  Sarepta Looks to Focus on Exondys 51 & DMD Pipeline in 2017 Zacks
Jun-29-17 04:21PM  Could This Biotech Be Headed For A Deal After CEO Takes Reins? Investor's Business Daily
01:20PM  A Veteran CEO Might Be Just What Sarepta Therapeutics Needed Benzinga
10:25AM  Sarepta Appoints Ex-Allergan Executive as CEO and President Zacks
10:12AM  Sarepta: A New CEO Goes a Long Way? Barrons.com
Jun-28-17 06:58PM  Sarepta Therapeutics names new CEO MarketWatch
06:37PM  [$$] Sarepta Taps Chase Pharmaceuticals Chief as Next CEO The Wall Street Journal
05:14PM  Sarepta appoints former Allergan executive Douglas Ingram as CEO Reuters
04:01PM  Sarepta Therapeutics Appoints Douglas S. Ingram as President and Chief Executive Officer GlobeNewswire
09:05AM  Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : SRPT-US : June 28, 2017 Capital Cube
08:30AM  Sarepta Therapeutics to Announce Second Quarter 2017 Financial Results and Recent Corporate Developments on July 19, 2017 GlobeNewswire
Jun-27-17 08:30AM  Sarepta Therapeutics Announces Grand Opening of its Research and Manufacturing Center at Andover GlobeNewswire
Jun-21-17 01:30PM  Scott+Scott, Attorneys at Law, LLP Reminds Investors of its Investigation of Sarepta Therapeutics, Inc. Business Wire +5.55%
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD. The company has a strategic alliance with Nationwide Children's Hospital for the advancement of microdystrophin gene therapy program under the research and option agreement, as well as Galgt2 gene therapy program under the license agreement; Catabasis Pharmaceuticals, Inc to explore a combination drug treatment approach for DMD under the research collaboration agreement; and Charley's Fund, Inc. to support the development of product candidates using its proprietary exon-skipping technologies under the research agreement. It also has a license agreement with the University of Western Australia for treatment of DMD by inducing the skipping of certain exons; collaboration and license agreement with Summit (Oxford) Ltd. for the development of ezutromid, an utrophin modulator which is in phase II clinical trials for the treatment of DMD; and a gene therapy research collaboration with Genethon to develop treatments for Duchenne muscular dystrophy. The company distributes its products through a network of specialty distributors and specialty pharmacies in the United States. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
INGRAM DOUGLAS SPresident & CEOJul 27Buy42.5047,0581,999,965382,058Jul 28 08:51 AM
Howton David TSVP, General CounselJul 21Option Exercise20.561,00020,56523,301Jul 21 09:46 PM
Mahatme SandeshEVP, CFO & CBOJul 21Option Exercise23.851,50035,77533,861Jul 21 09:49 PM
Ruff ShamimSVP, Regulatory Affairs & QualJul 21Option Exercise14.125,88883,13325,450Jul 21 09:47 PM
Ruff ShamimSVP, Regulatory Affairs & QualJul 21Sale44.004,388193,07221,062Jul 21 09:47 PM
Ruff ShamimSVP, Regulatory Affairs & QualJul 20Option Exercise13.716,25085,68827,312Jul 21 09:47 PM
Mahatme SandeshEVP, CFO & CBOJul 20Option Exercise15.3850,000769,10765,359Jul 21 09:49 PM
Cumbo AlexanderSVP, Chief Commercial OfficerJul 20Option Exercise13.712,50034,27522,793Jul 21 09:45 PM
Howton David TSVP, General CounselJul 20Option Exercise13.7125,000342,75041,357Jul 21 09:46 PM
Howton David TSVP, General CounselJul 20Sale41.0025,0001,025,00022,301Jul 21 09:46 PM
Cumbo AlexanderSVP, Chief Commercial OfficerJul 20Sale41.005,918242,63816,875Jul 21 09:45 PM
Mahatme SandeshEVP, CFO & CBOJul 20Sale41.0050,0002,050,00032,361Jul 21 09:49 PM
Kaye Edward M. MDDirectorJul 20Sale41.0010,000410,00052,471Jul 21 09:48 PM
Ruff ShamimSVP, Regulatory Affairs & QualJul 20Sale42.006,250262,50021,062Jul 21 09:47 PM
Howton David TSVP, General CounselNov 09Option Exercise23.851,00023,85022,453Nov 10 08:27 AM
Mahatme SandeshSenior Vice President, CFONov 09Option Exercise23.851,00023,85032,532Nov 10 08:26 AM
Kaye Edward M. MDPresident, CEO & CMONov 09Option Exercise8.283,00024,84075,635Nov 10 08:19 AM
Ruff ShamimSVP, Regulatory Affairs & QualNov 08Option Exercise26.241,00026,24021,239Nov 10 08:20 AM
Mahatme SandeshSenior Vice President, CFOOct 17Option Exercise13.9030,000417,00061,532Oct 19 04:22 PM
Mahatme SandeshSenior Vice President, CFOOct 17Sale50.0830,0001,502,50231,532Oct 19 04:22 PM
Howton David TSVP, General CounselSep 22Option Exercise13.907,00097,30028,453Sep 26 04:19 PM
Kaye Edward M. MDPresident, CEO & CMOSep 22Option Exercise8.2840,179332,682117,162Sep 26 04:23 PM
Ruff ShamimSVP, Regulatory Affairs & QualSep 22Option Exercise13.907,311101,62327,550Sep 30 09:58 PM
Ruff ShamimSVP, Regulatory Affairs & QualSep 22Sale60.007,311438,66020,239Sep 30 09:58 PM
Kaye Edward M. MDPresident, CEO & CMOSep 22Sale60.0040,1792,410,74076,983Sep 26 04:23 PM
Howton David TSVP, General CounselSep 22Sale60.007,000420,00021,453Sep 26 04:19 PM